Design
Phase 3, double-blind randomized controlled trial
Evidence chain
Population
1,961 adults with overweight or obesity, without diabetes.
Intervention and comparator
Semaglutide plus lifestyle intervention versus placebo plus lifestyle intervention for 68 weeks.
Endpoint
Change in body weight and categorical weight-loss thresholds.
Reported result
Mean body-weight change was −15.3 kg with semaglutide and −2.6 kg with placebo; 86.4% versus 31.5% achieved at least 5% weight reduction.
Leptox interpretation
A large efficacy signal in the studied population and protocol; it does not by itself determine individual suitability or outcomes after discontinuation.